EirGen Pharma Product Eir-101 receives US ANDA Approval

EirGen Pharma are pleased to announce that our in-house developed oral breast cancer treatment Eir-101 has received approval for sale by US FDA. This is a first to file generic product with US market sales of  $15M per annum and commercial supplies are expected to ship shortly.